Royalty Pharma Soars Up to 65% After Year’s Biggest U.S. IPO

(Bloomberg) -- Royalty Pharma Plc, a buyer of biopharmaceutical royalties, rose a much as 65% in its trading debut after its upsized initial public offering raised $2.18 billion with shares priced ...